19
Participants
Start Date
April 10, 2017
Primary Completion Date
July 1, 2019
Study Completion Date
July 1, 2019
Minnelide
Minnelide will be administered at the dose of 0.67 mg/m2 as a 30 min infusion intravenously daily on days 1-21 of each cycle followed by a 7 day rest period (days 22-28).
University of Pennsylvania, Philadelphia
HonorHealth Research Institute, Scottsdale
Moores UC San Diego Cancer Center, La Jolla
Lead Sponsor
Collaborators (1)
Barts & The London NHS Trust
OTHER
Translational Genomics Research Institute
OTHER
Stand Up To Cancer
OTHER
Cancer Research UK
OTHER
Lustgarten Foundation
OTHER
Queen Mary University of London
OTHER
Minneamrita Therapeutics LLC
INDUSTRY